Remove 2026 Remove Chemotherapy Remove Vaccines
article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.

FDA
article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

How will RFK Jr’s American dream for vaccines play out? Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

FDA